Author response: A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer

Abstract

Combination of glutaminase inhibitor CB-839 and ASCT2 inhibitor V-9302 showed efficient antitumor effect against glutamine addicted liver cancer cells via glutathione depletion and reactive oxygen species (ROS) induction.

Authors 14

1. Haojie Jin

   Shanghai Jiao Tong University · Renji Hospital · The Netherlands Cancer Institute · Shanghai Cancer Institute · Oncode Institute · State Key Laboratory of Oncogene and Related Genes

   Affiliation as printed

   Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute

   State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine

2. Siying Wang

   Shanghai Jiao Tong University · Renji Hospital · Shanghai Cancer Institute · State Key Laboratory of Oncogene and Related Genes

   Affiliation as printed

   State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine

3. Esther A. Zaal

   Utrecht University

   Affiliation as printed

   Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht University

4. Cun Wang

   Shanghai Jiao Tong University · Renji Hospital · The Netherlands Cancer Institute · Shanghai Cancer Institute · Oncode Institute · State Key Laboratory of Oncogene and Related Genes

   Affiliation as printed

   Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute

   State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine

5. Hai-Qiu Wu Aachen Department of Cell and Chemical Biology

   Leiden University · Leiden University Medical Center

   Affiliation as printed

   Department of Cell and Chemical Biology, Leiden University Medical Centre

6. Astrid R. Bosma

   The Netherlands Cancer Institute · Oncode Institute

   Affiliation as printed

   Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute

7. Fleur Jochems

   The Netherlands Cancer Institute · Oncode Institute

   Affiliation as printed

   Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute

8. Nikita Isima

   The Netherlands Cancer Institute · Oncode Institute

   Affiliation as printed

   Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute

9. Guang‐Zhi Jin

   Second Military Medical University · Eastern Hepatobiliary Surgery Hospital

   Affiliation as printed

   Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University

10. Cor Lieftink

    The Netherlands Cancer Institute · Oncode Institute

    Affiliation as printed

    Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute

11. Roderick L. Beijersbergen

    The Netherlands Cancer Institute · Oncode Institute

    Affiliation as printed

    Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute

12. Celia R. Berkers

    Utrecht University

    Affiliation as printed

    Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht University

    Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University

13. Wenxin Qin

    Shanghai Jiao Tong University · Renji Hospital · Shanghai Cancer Institute · State Key Laboratory of Oncogene and Related Genes

    Affiliation as printed

    State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine

14. René Bernards

    The Netherlands Cancer Institute · Oncode Institute

    Affiliation as printed

    Division of Molecular Carcinogenesis, Oncode Institute. The Netherlands Cancer Institute